LY4066708

· Eli Lilly and Company

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for LY4066708, covering 2026-03-03 to 2026-03-03. Get the full timeline:

Most recent: Clinical Trial Update: A Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY4066708 in Healthy Participants [Phase 1]

See pricing